Xenon Pauses Depression Trials on Safety Concerns, Stock Plunges 25%
XENE sits 18% above its 52-week low of $35.97.
Summary
Xenon's NDA filing for azetukalner in focal seizures is overshadowed by a pause in enrollment for major depressive disorder and bipolar depression studies due to neuropsychiatric adverse events. The company says the events align with the drug's known safety profile but hadn't appeared earlier in testing, and it is evaluating dosing modifications. Shares cratered 25% to $42.84 in premarket trading, the largest single-day drop since March 2017. Deutsche Bank downgraded the stock to Hold, while Wells Fargo maintained Overweight, arguing no negative read-through for focal seizures. This follows the NDA filing reported yesterday, but the clinical setback is new and materially changes the risk profile for the broader azetukalner program.
At the time of this announcement, XENE was trading at $42.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $35.97 to $72.66. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.